Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will be presenting at two conferences in November 2016. The details are as follows:
CreditSuisse 25th Annual Healthcare Conference
Monday, November 7 from 4:30 to 5:00 p.m. (MST)
The Phoenician Hotel, Scottsdale, Arizona
Webcast Link (archived for 90 days): CreditSuisse Innoviva Presentation
Stifel 2016 Healthcare Conference
Wednesday, November 16 from 10:15 to 10:55 a.m. (EST)
Lotte New York Palace Hotel, New York
Webcast Link (archived for 90 days): Stifel Innoviva Presentation
Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innoviva's website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005440/en/Business Wire
Last updated on: 31/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.